Cagrilintide

1. Quick Facts

2. Summary

Cagrilintide is a long-acting amylin receptor agonist developed for appetite suppression and body weight reduction research.

The compound is frequently discussed alongside GLP-1 receptor agonists because of potentially complementary appetite-regulating effects. Among investigational metabolic peptides, Cagrilintide possesses substantially stronger human clinical evidence than many compounds commonly discussed within peptide communities. Clinical studies have demonstrated meaningful effects on appetite regulation, caloric intake, and body weight reduction. :contentReference[oaicite:0]{index=0}

What People Commonly Claim

• More powerful appetite suppression than GLP-1 receptor agonists alone
• Superior weight loss when combined with semaglutide
• Reduced food noise and cravings
• Less muscle loss during dieting
• A next-generation obesity treatment that may outperform current therapies

What the Literature Actually Shows

• Cagrilintide is a long-acting amylin receptor agonist specifically developed for weight management research.
• Human clinical trials have demonstrated meaningful reductions in body weight and caloric intake.
• Combination therapy with semaglutide has shown greater weight-loss effects than either mechanism alone in multiple studies.
• Gastrointestinal side effects remain common and appear similar to those observed with other appetite-suppressing therapies.
• While results have been promising, long-term comparative data against newer multi-receptor obesity therapies remain limited.

3. Reconstitution Guide

At this concentration:
• 250 mcg = 0.050 mL (5.0 units)
• 2.4 mg = 0.480 mL (48.0 units)

*Different vial sizes may limit reconstitution volume. If your product differs from the specifications listed here, please use the Peptide Calculator to calculate custom concentrations and dosing protocols.

4. Route of Administration

Cagrilintide is most commonly administered as a subcutaneous injectable metabolic peptide compound.

5. Common Research Protocols

6. Mechanism of Action

Cagrilintide mimics amylin signaling pathways involved in satiety, gastric emptying, and appetite regulation.

Potential downstream effects discussed in research include:

• Reduced appetite signaling
• Enhanced satiety
• Slower gastric emptying
• Reduced caloric intake
• Potential synergy with GLP-1 receptor agonists

Its extended half-life supports once-weekly administration patterns. Human pharmacokinetic studies have demonstrated a half-life generally measured in days rather than hours, supporting sustained receptor activation between doses. :contentReference[oaicite:1]{index=1}

7. Potential Benefits

• Significant appetite suppression
• Reduced caloric intake
• Potential body weight reduction
• Possible synergy with GLP-1 compounds
• Reduced food preoccupation in anecdotal reports
• Convenient once-weekly administration

8. Potential Risks / Side Effects

Moderate

• Nausea
• Vomiting
• Constipation
• Fatigue
• Dizziness
• Reduced appetite to problematic levels
• Potential gastrointestinal discomfort
• Limited long-term human safety data

9. Half-Life

Cagrilintide is commonly discussed as having an estimated half-life approaching approximately one week.

Human pharmacokinetic studies have reported half-lives generally ranging from approximately 159 to 195 hours, supporting once-weekly administration schedules. :contentReference[oaicite:2]{index=2}

This extended duration is one reason why once-weekly administration protocols are widely discussed.

10. Storage Information

• Store refrigerated before and after reconstitution
• Protect from direct light exposure
• Avoid repeated freeze-thaw cycles
• Maintain sterile handling practices during preparation

11. Contraindications / Warnings

• Pregnancy or breastfeeding
• Severe gastrointestinal disorders
• History of pancreatitis
• Severe eating disorders
• Known hypersensitivity to peptide compounds

12. Further Study

Cagrilintide is one of the more extensively studied investigational metabolic peptides currently in development. Unlike many research compounds discussed online, its appetite-suppressing and weight-management effects have been evaluated in multiple human clinical trials. :contentReference[oaicite:3]{index=3}

Tier 1 — Essential Reading

Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (CagriSema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis
A comprehensive review of available human evidence for both cagrilintide and CagriSema.

Expanding the Treat-to-Target Toolbox for Obesity and Related Complications
Reviews emerging obesity therapies and the evolving role of cagrilintide-based treatment strategies.

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1)
Landmark Phase 3a trial evaluating combined cagrilintide and semaglutide therapy.

Tier 2 — Specialized Applications

• Amylin receptor biology and appetite regulation
• Combination therapy with GLP-1 receptor agonists
• Long-term obesity management strategies
• Metabolic effects beyond weight reduction
• Cardiometabolic risk reduction research

CKF Note: Additional clinical trials exist for Cagrilintide and CagriSema; however, many primary publications remain available only through journal subscriptions. Consistent with CKF policy, only freely accessible full-text resources should be included whenever possible.

Tier 3 — Controversies, Limitations, and Evidence Gaps

• Long-term durability of weight loss
• Comparative efficacy versus newer multi-receptor obesity therapies
• Body-composition and muscle-preservation claims
• Real-world adherence and tolerability
• Long-term safety beyond currently available trial durations

CKF Note: Unlike many experimental peptides, Cagrilintide has been evaluated in multiple human clinical trials. While questions remain regarding long-term outcomes and optimal combination strategies, the compound’s appetite-suppressing and weight-loss effects are supported by substantially stronger evidence than is available for many research peptides. :contentReference[oaicite:4]{index=4}

13. Research References

• PubMed
• PubMed Central (PMC)
• NIH Publications
• Metabolic disease and obesity literature
• Peer-reviewed incretin and amylin research journals

14. Last Reviewed

June 2026